| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | BridgeBio Pharma, Inc. | Sep 29, 2026 | |
| Buy | BridgeBio Pharma, Inc. | May 11, 2026 | |
| Buy | BridgeBio Pharma, Inc. | Apr 29, 2026 | |
| Buy | BROADRIDGE FINANCIAL SOLUTIO | Apr 2, 2026 | |
| Buy | BridgeBio Pharma, Inc. | Mar 19, 2026 | |
| Buy | BridgeBio Pharma, Inc. | Mar 18, 2026 | |
| Buy | BridgeBio Pharma, Inc. | Mar 3, 2026 | |
| Buy | BridgeBio Pharma, Inc. | Sep 22, 2025 | |
| Buy | BridgeBio Pharma, Inc. | Aug 8, 2025 |
This page tracks congressional stock trading activity in BridgeBio Pharma, Inc. (BBIO) in the Healthcare sector. Disclosed Capitol has indexed 9 disclosed congressional trades involving BBIO. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 9 disclosed congressional trades in BridgeBio Pharma, Inc. (BBIO) — 8:1 buy-heavy ratio — led by Gilbert Cisneros (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Cisneros | D | Sell | $1,001 - $15,000 |
| May 11, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Apr 29, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Apr 2, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Mar 19, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Mar 18, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Mar 3, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Sep 22, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Aug 8, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
Across the 9 disclosed congressional trades in BridgeBio Pharma, Inc. (BBIO), members of Congress have reported 8 buys and 1 sell. The average 30-day alpha vs. the S&P 500 is 2.48%.
For fiscal year 2025, BridgeBio Pharma, Inc. reported revenue of $502.1M and net income of -$724.9M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $243.7M, net income -$152.2M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.